Drug interactions between Adriamycin and chlorambucil
Interactions between your drugs
Applies to: chlorambucil and Adriamycin (doxorubicin)
Consumer information for this interaction is not currently available.
MONITOR: The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.
MANAGEMENT: Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.
- "Product Information. Ellence (epirubicin)" Pharmacia and Upjohn, Kalamazoo, MI.
- Agencia Española de Medicamentos y Productos Sanitarios Healthcare "Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ():
- "Product Information. Paraplatin (carboplatin)." Bristol-Myers Squibb, Princeton, NJ.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.
- "Product Information. Zanosar (streptozocin)." Pharmacia and Upjohn, Kalamazoo, MI.
- "Product Information. Fluorouracil injection (fluorouracil)." Roche Laboratories, Nutley, NJ.
- EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."
Drug and food interactions
No results found in our database - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.